Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-omburtamab for Neuroblastoma CNS/Leptomeningeal Metastases
NCT03275402Phase 3Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Dec 2018
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of 131I-omburtamab in neuroblastoma, sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Overall Survival Rate at 3 years. Started Dec 2018; status: terminated.
02
Drugs
131I-omburtamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03275402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275402.